A Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients Switched From EC-MPS.
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will assess the safety, efficacy and effect on quality of life of switching kidney
transplant patients from reduced dose EC-MPS treatment due to gastrointestinal problems to a
higher than the equimolar dose of CellCept. Patients will be switched, initially, from EC-MPS
(<1440g/day) to an equimolar dose of CellCept, and at the next visit (day 10 +/- 5) the
CellCept dose will be increased by 250mg/day, and the daily dose will be split into 3-4
doses. The anticipated time on study treatment is <3 months, and the target sample size is
<100 individuals.